Ekso Bionics Announces $4.6 Million Registered Direct Offering
January 11 2024 - 7:00AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced that it has entered into a
securities purchase agreement with certain institutional investors
for the purchase and sale of 2,967,742 shares of common stock at a
purchase price of $1.55 per share pursuant to a registered direct
offering, resulting in total gross proceeds of approximately $4.6
million before deducting placement agent commissions and other
offering expenses. The closing of the offering is expected to occur
on or about January 16, 2024, subject to the satisfaction of
customary closing conditions.
The Company intends to use the net proceeds from
the offering for working capital and general corporate
purposes.
A.G.P./Alliance Global Partners is acting as the
sole placement agent for the offering.
This offering is being made pursuant to an
effective shelf registration statement on Form S-3 (File No.
333-272607) previously filed with the U.S. Securities and Exchange
Commission (the “SEC”). The offering is made only by means of a
prospectus supplement and accompanying prospectus, which will be
filed with the SEC and will be available on the SEC's website
located at http://www.sec.gov. Electronic copies of the prospectus
supplement may be obtained, when available, from A.G.P./Alliance
Global Partners, 590 Madison Avenue, 28th Floor, New York, NY
10022, or by telephone at (212) 624-2060, or by email at
prospectus@allianceg.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Ekso Bionics®
Ekso Bionics® is a leading developer of
exoskeleton solutions that amplify human potential by supporting or
enhancing strength, endurance and mobility across medical and
industrial applications. Founded in 2005, the Company continues to
build upon its industry-leading expertise to design some of the
most cutting-edge, innovative wearable robots available on the
market. Ekso Bionics is the only known exoskeleton company to offer
technologies that range from helping those with paralysis to stand
up and walk, to enhancing human capabilities on job sites across
the globe. The Company is headquartered in the San Francisco Bay
Area and is listed on the Nasdaq Capital Market under the symbol
“EKSO.”
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements. Forward-looking statements include,
without limitation, statements relating to the Company’s offering
of securities and the use of proceeds from such offering.
Forward-looking statements can be identified by words such as
“expect,” “continue,” “anticipate,” “estimate,” “believe,” “plan,”
“projection,” “grow,” “potential,” “future,” “can,” “develop,”
“proposition,” “position,” “expand,” “may” or words of similar
meaning. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of risks and uncertainties.
Factors that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company’s liquidity position and its ability to
raise additional funds, as well as changes in general economic and
market conditions. These and other factors are identified and
described in more detail in the Company's public filings with the
Securities and Exchange Commission (“SEC”). You should carefully
read the Cautionary Note Regarding Forward-Looking Statements and
the factors described in the “Risk Factors” section of the
Company’s periodic reports filed with the Securities and Exchange
Commission to better understand the risks and uncertainties
inherent in the Company. The Company does not undertake to update
these forward-looking statements, except as required by law.
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2024 to Jun 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Jun 2023 to Jun 2024